Delamanid and bedaquiline resistance in mycobacterium tuberculosis ancestral Beijing genotype causing extensively drug-resistant tuberculosis in a tibetan refugee

American Journal of Respiratory and Critical Care Medicine

Volumn 193, Issue 3, 2016, Pages 337-340

  Hoffmann, Harald ^a,b   Kohl, Thomas A ^c   Hofmann Thiel, Sabine ^a,b   Merker, Matthias ^c,d   Beckert, Patrick ^c,d   Jaton, Katia ^e   Nedialkova, Lubov ^b   Sahalchyk, Evgeni ^b   Rothe, Thomas ^f   Keller, Peter M ^g   Niemann, Stefan ^c  

^a SYNLAB ACADEMY   (Germany)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c RESEARCH CENTER BORSTEL   (Germany)

^d German Center for Infection Research   (Germany)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f Zurcher Hohenklinik Davos   (Switzerland)

^g Institut fur Medizinische Mikrobiologie   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; BEDAQUILINE; CAPREOMYCIN; CLOFAZIMINE; COTRIMOXAZOLE; CYCLOSERINE; DELAMANID; ETHAMBUTOL; LEVOFLOXACIN; NITROIMIDAZOLE DERIVATIVE; OPC-67683; OXAZOLE DERIVATIVE; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL GENE; BACTERIAL GENOME; BACTERIUM ISOLATE; CASE REPORT; COMPASSIONATE USE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FBIA GENE; GENE MUTATION; GENETIC VARIABILITY; HUMAN; LETTER; LUNG LOBECTOMY; MAXIMUM LIKELIHOOD METHOD; MINIMUM INHIBITORY CONCENTRATION; MUTATOR GENE; MYCOBACTERIUM TUBERCULOSIS; NEXT GENERATION SEQUENCING; PLESIOMORPHY; PRIORITY JOURNAL; REFUGEE; REGULATOR GENE; TIBETAN (PEOPLE); CHINA; DRUG EFFECTS; ETHNOLOGY; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GENETICS; GENOTYPE; MALE; MICROBIOLOGY; MULTIDRUG RESISTANCE; TIBET;

ADULT; ANTITUBERCULAR AGENTS; BEIJING; COMPASSIONATE USE TRIALS; DIARYLQUINOLINES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GENOTYPE; HUMANS; MALE; MYCOBACTERIUM TUBERCULOSIS; NITROIMIDAZOLES; OXAZOLES; REFUGEES; TIBET;

EID: 84973911525     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201502-0372LE     Document Type: Letter

References (16)

1. World Health Organization. Global tuberculosis report 2014. Geneva: World Health Organization; 2014 [accessed 2015 Feb 9]. Available from: http://apps. who. int/iris/bitstream/10665/137094/1/ 9789241564809-eng. pdf?ua=1
2. Blair HA, Scott LJ. Delamanid: A review of its use in patients with multidrug-resistant tuberculosis. Drugs 2015;75:91-100.
3. Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, Leimane V, Andries K, Bakare N, De Marez T, et al.; TMC207-C208 Study Group. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014;371:723-732.
4. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012;366:2151-2160.
5. Somoskovi A, Bruderer V, Hömke R, Bloemberg GV, Böttger EC. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment. Eur Respir J 2015;45:554-557.
6. Hartkoorn RC, Uplekar S, Cole ST. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014;58:2979-2981.
7. Keller PM, Hömke R, Ritter C, Valsesia G, Bloemberg GV, Böttger EC. Determination of MIC distribution and epidemiological cutoff valuesfor bedaquiline and delamanid in Mycobacterium tuberculosis using the MGIT 960 system equipped with TB eXiST. Antimicrob Agents Chemother 2015;59:4352-4355.
8. Martin A, Paasch F, Docx S, Fissette K, Imperiale B, Ribón W, González LA, Werngren J, Engström A, Skenders G, et al. Multicentre laboratory validation of the colorimetric redox indicator (CRI) assay for the rapid detection of extensively drug-resistant (XDR) Mycobacterium tuberculosis. J Antimicrob Chemother 2011;66:827-833.
9. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, Shimokawa Y, Komatsu M. OPC-67683, a nitro-dihydroimidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006;3:e466.
10. European Medicines Agency. Delamanid assessment report. London, UK: European Medicines Agency; 2014. EMA/55567/2014.
11. Merker M, Blin C, Mona S, Duforet-Frebourg N, Lecher S, Willery E, Blum MG, Rüsch-Gerdes S, Mokrousov I, Aleksic E, et al. Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage. Nat Genet 2015;47:242-249.
12. Bashiri G, Rehan AM, Greenwood DR, Dickson JM, Baker EN. Metabolic engineering of cofactor F420 production in Mycobacterium smegmatis. PLoS One 2010;5:e15803.
13. Hartkoorn RC, Ryabova OB, Chiarelli LR, Riccardi G, Makarov V, Cole ST. Mechanism of action of 5-nitrothiophenes against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014;58:2944-2947.
14. Feuerriegel S, Köser CU, Baù D, Rüsch-Gerdes S, Summers DK, Archer JA, Marti-Renom MA, Niemann S. Impact of Fgd1 and ddn diversity in Mycobacterium tuberculosis complex on in vitro susceptibility to PA-824. Antimicrob Agents Chemother 2011;55:5718-5722.
15. Choi KP, Kendrick N, Daniels L. Demonstration that fbiC is required by Mycobacterium bovis BCG for coenzyme F(420) and FO biosynthesis. J Bacteriol 2002;184:2420-2428.
16. Forouhar F, Abashidze M, Xu H, Grochowski LL, Seetharaman J, Hussain M, Kuzin A, Chen Y, Zhou W, Xiao R, et al. Molecular insights into the biosynthesis of the F420 coenzyme. J BiolChem2008;283:11832-11840.